Sanofi joins Eli Lilly and Novo Nordisk in capping insulin prices at $35 per month.

Sanofi plans to cut the US price of its most popular insulin drug by 78% and cap monthly out-of-pocket costs at $35 for people who have private insurance starting next year. The French drugmaker will also reduce the list price of its short-acting insulin Apidra by 70%. Sanofi is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts for the lifesaving hormone. Eli Lilly and Novo Nordisk made similar sweeping cuts earlier this month after years of political pressure and public outrage over the high costs of diabetes care.